University of North Carolina School of Law
From the SelectedWorks of Andrew Chin

February 2, 2011

Gene Probes as Unpatentable Printed Matter
Andrew Chin

Available at: https://works.bepress.com/andrew_chin/2/

GENE PROBES AS UNPATENTABLE PRINTED MATTER

Andrew Chin*
ABSTRACT
In this Article, I argue that the most problematic kind of gene
patents — those claiming short DNA molecules used to probe for longer
gene sequences — should be held invalid as directed to unpatentable printed
matter.

This argument, which emerges from recent developments in

biotechnology and information technology, is grounded in the printed
matter doctrine’s structural role of obviating patentability inquiries directed
to inapposite information-management considerations. Where the inventive
contribution in a claimed gene probe subsists solely in stored sequence
information, these inapposite considerations lead the novelty and
nonobviousness analyses to anomalous results that the printed matter
doctrine was designed to avoid. I conclude that the doctrine should apply to
all gene probes capable of being synthesized by known general methods.
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I. INTRODUCTION

So-called “gene patent” claims are often actually directed to gene
probes.1 A gene probe is a short nucleic acid molecule (also known as an
“oligonucleotide”) that can be used to detect the presence of complementary
sequences in a genetic sample.2 For example, two of the claims challenged
by the American Civil Liberties Union and numerous public health
organizations in the recent Myriad Genetics case3 cover any “isolated DNA
having at least 15 nucleotides” of the DNA sequence encoding BRCA1, a
protein associated with breast cancer,4 based on its utility as a gene probe in

1

See Christopher M. Holman, The Impact of Human Gene Patents on

Innovation and Access: A Survey of Human Gene Patent Litigation, 76
UMKC L. REV. 295, 313-14 (2007).
2

See I. EDWARD ALCAMO, FUNDAMENTALS

OF

MICROBIOLOGY 633

(2001).
3

Association for Molecular Pathology v. United States Patent &

Trademark Office, 702 F. Supp. 2d 181 (S.D.N.Y. 2010) [hereinafter
Myriad].

Co-defendants Myriad Genetics and the University of Utah

Research Foundation are the owners of the patents in suit. Id. at 184.
4

U.S. Patent No. 5,747,282, claims 5-6 (issued May 5, 1998).
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various diagnostic procedures.5
Like the patenting of genetic material more generally,6 the patenting of
gene probes has been controversial. Appealing to the intimate connections
between the human genome and the life, identity and shared heritage of the
human species, some commentators have expressed ethical concerns over
the commodification and propertization of parts of the human genome,
concerns that extend to both full-length genes and gene probes.7 Other

5

Id. at cols. 11-17.

6

See generally Andrew Chin, Research in the Shadow of DNA Patents,

87 J. PATENT & TRADEMARK OFFICE SOC’Y 846, 854-78 (2005) (surveying
the controversy over gene patenting).
7

See, e.g., Baruch Brody, Protecting Human Dignity and the Patenting

of Human Genes, in A. Chapman, ed., PERSPECTIVES ON GENE PATENTING
111-26 (1999) (“[I]t is wrong to commercialize something with which
individuality and personhood is intertwined”); see also Mark J. Hanson,
Biotechnology and Commodification Within Health Care, 24 J. MED. &
PHIL. 267 (1999) (“If the rhetoric regarding our genes becomes increasingly
commodified at a time when media reports continue to strengthen the link
between genes and human traits that centrally define us both as a species
and as individuals, a subtle but not insignificant offense to notions of

4
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scholars have argued that the disclosures supporting gene probe patents
provide the public with only preliminary characterizations of genetic
sequences while precluding a broad range of downstream research on
diagnostic and therapeutic techniques,8 as well as parallel research directed

personhood and concomitant self-perception may occur.”); Richard D. Land
& C. Ben Mitchell, Patenting Life: No, 63 FIRST THINGS 20, 20-22 (1996)
(condemning the patenting of genes as an illegitimate effort to claim that
which can only be owned by God); U.S. Coalition Counters Breast Gene
Patents, 381 NATURE 265 (1996) (reporting women’s organizations’
criticism that breast cancer gene probe patents deny women “control over
the most intimate aspect of their being, their bodies’ genetic blueprint.”).
8

See, e.g., Thomas Kiley, Patents on Random Complementary DNA

Fragments, 257 SCIENCE 915 (1992) (“These patents cluster around the
earliest imaginable observations on the long road toward practical benefit,
while seeking to control what lies at the end of it.”); Cara Koss, Note,
Oysters & Oligonucleotides: Concerns and Proposals for Patenting
Research Tools, 25 CARDOZO ARTS & ENT. L.J. 747, 754-58 & n.67 (2007)
(describing the granting of oligonucleotide patents of dubious utility);
Cynthia D. Lopez-Beverage, Should Congress Do Something About
Upstream Clogging Caused By the Deficient Utility of Expressed Sequence
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toward identifying other patentable gene probes.9

5

Concerns over the

development of a research anticommons10 have led to some notable
defensive publication efforts, including the Merck Gene Index and the SNP

Tag Patents?, 10 J. TECH. L. & POL’Y 35, 76-85 (2005) (describing the poor
quality and preclusive effects of gene fragment patents); John F. Merz et al.,
Diagnostic Testing Fails the Test, 415 NATURE 577 (2002); American
College of Medical Genetics, Position Statement on Gene Patents and
Accessibility

of

Gene

Testing

(visited

‹http://www.faseb.org/genetics/acmg/pol-34.htm›

June

6,

(“[R]estricting

2002)
the

availability of gene testing ... retards the usually very rapid improvement of
a test that occurs through the addition of new mutations or the use of new
techniques by numerous laboratories that have accumulated samples from
affected individuals over many years.”).
9

See Chin, supra note 6, at 895 (showing how “existing patents on

oligonucleotides might impair the future search for patentable DNA
molecules, including other oligonucleotides”).
10

See Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter

Innovation? The Anticommons in Biomedical Research, 280 SCIENCE 698,
698-99 (1998).
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Consortium.11 More recently, critics of gene patents have taken aim at the
doctrinal distinction between patented isolated and purified nucleic acids
and unpatentable genetic materials occurring in nature,12 finding a

11

See Andrew Chin, Artful Prior Art and the Quality of DNA Patents,

57 ALA. L. REV. 975, 1016-18 (2006).
12

See John M. Conley, Gene Patents and the Product of Nature

Doctrine, 84 CHI.-KENT L. REV. 109 (2009); John M. Conley & Roberte
Makowski, Back to the Future: Rethinking the Product of Nature Doctrine
as a Barrier to Biotechnology Patents, 85 J. PAT. & TRADEMARK OFF.
SOC’Y 301 (2003); Linda J. Demaine & Aaron Xavier Fellmeth,
Reinventing

the

Double

Helix:

A

Novel

and

Nonobvious

Reconceptualization of the Biotechnology Patent, 55 STAN. L. REV. 303,
407-10 (2002) (arguing that isolation and purification of DNA molecules
would not pass the authors’ proposed “substantial transformation” test).

GENE PROBES AS UNPATENTABLE PRINTED MATTER

7

sympathetic ear in the district court in Myriad.13 None of these arguments,
however, has yet persuaded the Federal Circuit or the Patent Office.14
Patent claims directed to short DNA molecules raise particular concerns
about overbreadth because they typically cover all possible longer
sequences that include the claimed subsequence.15 In principle, such claims
should also be the most vulnerable to anticipation. General methods of
synthesizing oligonucleotides have been widely known and used since at

13

See Myriad, 702 F. Supp. 2d at 185 (citing Conley & Makowski,

supra note 10); id. at 232 (concluding that “the claimed isolated DNA is not
markedly different from native DNA as it exists in nature” and therefore
unpatentable).
14

See Chin, supra note 6, at 868-70 & 873-78 (discussing the Federal

Circuit’s and Patent Office’s responses to criticisms of gene patenting).
15

See Jasemine C. Chambers, Update on USPTO Practice: Tips for

Biotech Patent Prosecution, in BIOTECHNOLOGY LAW 2005, 840 PLI/Pat 7,
23-24 (2005) (explaining that a claim to an oligonucleotide “comprising at
least a portion” of a recited nucleotide sequence “contemplates additional
nucleotides”); Holman, supra note 1, at 314 (“In a practical sense, these
claims to probes and sequence fragments can provide more expansive
patent coverage than claims directed to the full-length gene sequence.”).

8
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least the 1980s.16 As I demonstrated in a previous article17 and the Federal
Circuit confirmed in In re Gleave,18 any prior art reference describing these
methods and listing any of the claimed oligonucleotide sequences would
anticipate and invalidate these claims under § 102(b).

It is trivial to

computer-generate and publish a list of all oligonucleotide sequences of a
given length, provided that such a list can be stored feasibly on a medium
that can be made accessible to the public.19 Thus the novelty of DNA
oligonucleotide claims hinges largely on whether structural definitions of
the claimed sequences have previously been typed out as A’s, C’s, G’s and
T’s in such a computer-generated list and published. Such a consideration
has more to do with the norms of the scientific community regarding
scholarly communication and with the availability of low-cost, highcapacity information storage media, than with the state of the art in
biotechnology.20

16

See infra note 76.

17

See Chin, supra note 11.

18

560 F.3d 1331 (Fed. Cir. 2009).

19

See Chin, supra note 11, at 1009-10.

20

See id. at 1021-23.
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Article argues

that

the patentability analysis

of

9
DNA

oligonucleotide claims should not reach these irrelevant considerations,
because DNA oligonucleotides capable of being synthesized by known
general methods should be held ineligible for patenting under patent law’s
printed matter doctrine. The printed matter doctrine serves to pre-empt
inapposite analyses of differences between the claimed invention and the
prior art — e.g., analyses focused on the management of stored information
rather than on the field of invention — that would otherwise be applied
under the novelty doctrine of § 102 or the nonobviousness doctrine of
§ 103.
As I will argue, the printed matter doctrine is applicable to DNA
oligonucleotide molecules because they are disposed to store nucleotide
sequence information in a manner analogous in all relevant respects to other
substrates that may be more intuitively recognizable as information storage
media, such as laser-printed text on paper. Moreover, to the extent that a
hybridization reaction involving a claimed oligonucleotide is recognized as
having specific and substantial utility, it is by virtue of the semantic
properties that scientists have attached to the complementary DNA
sequence, not an inventive functional relationship between the sequence
information and its molecular substrate.

While hybridization reactions

involving the claimed oligonucleotide probes may impart new and

10
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unobvious information regarding cancer, such information is useful and
intelligible only to the human mind and cannot confer patentability.
This Article opens a new front in the gene patenting debate. Until I
filed the Myriad amicus brief in the Federal Circuit on which this Article is
based,21 no one had ever challenged the validity of a gene patent on the
ground that it was directed to printed matter.22

While it is widely

recognized that DNA is “information embedded in a substrate of
molecules” and that “it is the informational content of a DNA molecule that
differentiates it from the prior art of other DNA molecules,”23 opponents of
gene patents have appealed to these characterizations only for the purpose
of arguing that genetic information is a phenomenon of nature.24 Such

21

Brief of Amici Curiae Scholars of Biotechnology Patent Law in

Support of Plaintiffs-Appellees, Supporting Affirmance, Association for
Molecular Pathology v. U.S. Patent & Trademark Office, No. 2010-1406
(Fed.

Cir.

filed

Dec.

7,

2010),

available

at

http://andrewchin.com/chin/outreach/myriadamicus.pdf.
22

See Kevin E. Collins, Semiotics 101: Taking the Printed Matter

Doctrine Seriously, 85 IND. L.J. 1379, 1389 n. 40 (2010).
23

See id. at 1389.

24

See, e.g., Myriad, 702 F. Supp. 2d at 194 (finding that “[G]enes and
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arguments have tended to conflate claimed DNA molecules with the
sequence information they contain, an approach the patent system has
vigorously rejected.25

In this Article, I share the view that DNA’s

the information represented by human gene sequences are products of
nature universally present in each individual”); U.S. Patent & Trademark
Office, Utility Examination Guidelines, 66 Fed. Reg. 1092, 1093 (Jan. 5,
2001) [hereinafter “Utility Guidelines”] (summarizing public comments to
the effect that “the sequence of the human genome is at the core of what it
means to be human and no person should be able to own/control something
so basic” or obtain patents “for discoveries in nature”); Bita Amani,
Patents, the Charter & A Healthy Dose of Rights in Wrongs: The Poison is
the Elixir for Life, Liberty & Security of the Person, 57 U.N.B. L.J. 162
(arguing that “genes are information” and are “our endowment from nature;
they are not invented”); Debra Greenfield, Intangible or Embodied
Information: The Non-Statutory Nature of Human Genetic Material, 25
SANTA CLARA COMPUTER & HIGH TECH. L.J. 467, 536 (2009) (arguing that
the law of nature exclusion should preclude the granting of patents “on the
exclusive use of genetic information”).
25

See Utility Guidelines, supra note 24, at 1093-94 (Jan. 5, 2001)

(acknowledging that “descriptive sequence information alone is not

12
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informational content is significant for patentability, but argue that it is an
insight more properly addressed to the printed matter doctrine than to the
product of nature exclusion.

II. DESCRIPTION AND PURPOSE OF THE PRINTED MATTER DOCTRINE

A. The Doctrine’s Broad Applicability

The printed matter doctrine states that “‘[m]ere printed matter can not
impart a patentable feature to a claim.’”26 The doctrine does not apply,
however, when there is a “new and unobvious functional relationship
between the printed matter and the substrate.”27

patentable subject matter” but explaining that a patent claim may be
directed to “a new and useful purified and isolated DNA compound
described by the sequence”).
26

In re Gulack, 703 F.2d 1381, 1385 (Fed. Cir. 1983) (quoting In re

Miller, 418 F.2d 1392 (C.C.P.A.1969)).
27

703 F.2d at 1386.
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As Judge Linn explained in In re Nuijten,28 the printed matter doctrine
precludes patentability where the differences between the claimed invention
and the prior art subsist merely in stored information:
Under the “printed matter” doctrine, if the only distinction
between a prior art storage medium and a claimed storage
medium is the information stored thereon — rather than a
different “functional relationship between the printed matter and
the substrate” — then the claimed storage medium (with
associated information) is unpatentably obvious over the prior
art because the information lacks “patentable weight.”29
The printed matter doctrine has survived the progression of printing
technologies from typewriters and treadle presses to laser printers and
nanolithography without having been limited to any particular kind of
storage medium.30 Instead, it extends to any physical substrate capable of
holding information, subject to the “functional relationship” limitation
noted above. Accordingly, courts over the years have proceeded to apply

28

500 F.3d 1346 (Fed. Cir. 2007).

29

Id. at 1365 (Linn, J., concurring-in-part and dissenting-in-part).

30

See id.

14
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the doctrine and its accompanying limitation in cases involving a wide
range of substrates.31

B. The Doctrine’s Structural Role

The printed matter doctrine has traditionally been viewed as an
elaboration of the § 101 patentable subject matter requirement.32 The

31

See, e.g., In re Bryan, 323 Fed.Appx. 898 (Fed. Cir. 2009)

(unpublished) (game boards); In re Gulack, 703 F.2d 1381 (Fed. Cir. 1983)
(paper, fabric or plastic bands); In re Miller, 418 F.2d 1392 (C.C.P.A.1969)
(measuring cups and spoons); Ex parte Gwinn, 112 U.S.P.Q. 439 (B.P.A.I
1955) (dice in a “parlor golf game”); In re Kothny, 96 F.2d 289 (C.C.P.A.
1938) (scales for measuring cylindrical records); In re McKee, 75 F.2d 991
(C.C.P.A. 1935) (meat products); In re Johns, 70 F.2d 913 (C.C.P.A. 1934)
(animal carcasses); In re Sterling, 70 F.2d 910 (C.C.P.A. 1934)
(checkbooks); Cincinnati Traction Co. v. Pope, 210 F. 443 (6th Cir. 1913)
(trolley transfer tickets).
32

See 1 CHISUM

ON

PATENTS § 1.02[4], at 1-24 (2006) (“‘[P]rinted

matter’ by itself did not constitute a ‘manufacture’”); see also Examination
Guidelines for Computer-Related Inventions, 61 Fed. Reg. 7478, 7481 (Feb.
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doctrine’s reliance on “patentable weight” considerations, however, is more
akin to a Graham analysis of the nonobviousness of the “differences
between the prior art and the claims at issue,”33 than the “claim as a whole”
approach that pervades modern patentable subject matter doctrine.34
Accordingly, the printed matter doctrine has also sometimes been applied as
part of a § 102 or § 103 analysis.35 Despite the ambiguous location of its
statutory basis, the printed matter doctrine has survived to the present day.36
As the Federal Circuit recently explained in King Pharmaceuticals, Inc.
v. Eon Labs.,37 the rationale behind the printed matter cases is “preventing
the indefinite patenting of known products by the simple inclusion of novel,

28, 1996) (instructing examiners to reject non-functional descriptive
material under § 101).
33

Graham v. John Deere Co., 383 U.S. 1, 17-18 (1966).

34

See Diamond v. Diehr, 450 U.S. 175, 189-91 (1981).

35

See, e.g., In re Ngai, 367 F.3d 1336 (Fed. Cir. 2004); In re Gulack,

703 F.2d 1381 (Fed. Cir. 1983); see also In re Nuijten, 500 F.3d 1346, 1365
(Fed. Cir. 2007) (Linn, J., concurring-in-part and dissenting-in-part)
(characterizing the doctrine as supporting a conclusion of obviousness).
36

See infra section II.C.

37

616 F.3d 1267 (Fed. Cir. 2010).

16
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yet functionally unrelated limitations.”38 The printed matter doctrine guards
against the diversion of patentability analysis into assessments of the
novelty and nonobviousness of information fixed in, but not conferring new
and nonobvious functionality upon, the underlying substrate.
In so doing, the printed matter doctrine serves alongside the judicially
created exceptions to patentable subject matter to pre-empt inapposite
analyses of differences between the claimed invention and the prior art that
would otherwise be applied under the novelty doctrine of § 102 and/or the
nonobviousness doctrine of § 103.39

Courts do not inquire into the

nonobviousness of newly discovered natural principles, because “the
discovery of some of the handiwork of nature . . . is not patentable . . .
however ingenious the discovery of that natural principle may have been.”40
Similarly, where “the only distinction between a prior art storage medium
and a claimed storage medium is the information stored thereon,”41 a

38

Id. at 1279.

39

Cf. Collins, supra note 22, at 1387 (explaining that the doctrine in

effect “excludes certain useful and nonobvious products of human ingenuity
from the patent regime”).
40

Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 131 (1948).

41

In re Nuijten, 500 F.3d at 1365.
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Graham analysis of the nonobviousness of the “differences between the
prior art and the claims at issue” would entail inquiries into the
nonobviousness of the stored information relative to prior art stored
information and the level of ordinary skill in information recombination,
regardless of the field of the underlying invention.42
Courts have consistently regarded such information-management
considerations as inapposite to the assessment of inventive contributions in
the relevant field of endeavor. For example, In re Russell43 dealt with a
directory in which surnames were arranged phonetically. The applicant
argued that his invention comprised “finished tangible subject matter
bearing specifically arranged data or means, combined to produce a novel
result.”44 The court affirmed the Patent Office’s rejection, holding: “The
mere arrangement of printed matter on a sheet or sheets of paper, in book
form or otherwise, does not constitute ‘any new and useful art, machine,
manufacture or composition of matter.’”45 This expression of the printed
matter doctrine served to obviate an irrelevant inquiry into the novelty and

42

See Graham v. John Deere Co., 383 U.S. at 17-18.

43

48 F.2d 668 (C.C.P.A. 1931).

44

Id. at 668.

45

Id. at 669.
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nonobviousness of the applicant’s “finished tangible” directory as an
information source relative to prior art directory and phonetic information
sources.
Similarly, in Guthrie v. Curlett,46 the patentee asserted a claim to a
“consolidated tariff index” that compiled the shipping rates set by numerous
transportation companies, using a system of symbols to facilitate a compact
presentation.47

The court credited the patentee with showing “how to

compress into small space a lot of information about freight tariffs,” but
explained that the proper subject of the patentability inquiry was the “means
. . . for making a consolidated index.”48 Finding the disclosed means to
consist solely of the non-novel “employment of symbols,” the court
concluded that the claim was directed to unpatentable subject matter.49 The
court thereby refrained from an inapposite inquiry into the ability of one
skilled in the art to combine and compress the information from prior art
individual tariff schedules into a single compact document.

46

10 F.2d 725 (2d Cir. 1926).

47

Id. at 725.

48

Id. at 726.

49

Id.
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In In re Ngai,50 the applicant invented a new procedure for normalizing
and amplifying RNA using a known reagent.51 The Patent Office allowed
his method claims, but rejected a claim directed to a kit combining the
reagent with instructions for performing the new procedure.52 The Federal
Circuit affirmed the rejection under the printed matter doctrine, finding that
the claimed invention amounted to “the addition of new printed matter to a
known product” with no functional relationship between the two: “Here the
printed matter in no way depends on the kit, and the kit does not depend on
the printed matter. All that the printed matter does is teach a new use for an
existing product. . . . If we were to adopt [applicant’s] position, anyone
could continue patenting a product indefinitely provided that they add a new
instruction sheet to the product.”53 The court’s application of the printed
matter doctrine thereby avoided a Graham inquiry as to whether one of
ordinary skill would have been able to assemble the claimed kit from the
prior art — a task that would entail producing and storing instructions for a

50

367 F.3d 1336 (Fed. Cir. 2004).

51

Id. at 1337.

52

Id. at 1337-38.

53

Id. at 1338-39.
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new and nonobvious procedure.54
Patent law’s novelty and nonobviousness doctrines are particularly illsuited to fact-specific assessments of the inventiveness embodied in stored
information, because these doctrines artificially construct the knowledge of
the person having ordinary skill in the art as including all publicly
accessible information resources, no matter how obscure.55 By obviating an
analysis directed to stylized facts and inapposite information-management
considerations, the printed matter doctrine preserves the integrity of the
novelty and nonobviousness doctrines as promoters of progress in the useful
arts.

54

See id. at 1338 (noting applicant’s attempt to distinguish the kit claim

by “argu[ing] that . . . prior art does not teach a limitation of ‘instructions
describing the method of [the method claim],’ combined with an
amplification kit”).
55

See, e.g., In re Hall, 781 F.2d 897 (Fed. Cir. 1986) (finding that “a

single cataloged thesis in one university library” was sufficiently accessible
to one exercising reasonable diligence to constitute a § 102(b) “printed
publication”).
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C. The Doctrine’s Continuing Operation

The printed matter doctrine is a long-established principle of patent law
that survived the enactment of the 1952 Patent Act.56 While there is some
ambiguity today as to which section of the 1952 Act supplies its statutory
basis,57 the doctrine has never been repudiated in over a century.58
In particular, the Supreme Court’s recent decision in Bilski v. Kappos59
did not disturb the printed matter doctrine, not least because the doctrine

56

See, e.g., In re Miller, 418 F.2d 1392 (C.C.P.A. 1969); In re Russell,

42 F.2d 668 (C.C.P.A. 1931); U.S. Credit System Co. v. Am. Credit
Indemnity Co., 59 F. 139, 143 (2d Cir. 1893); see generally Harold C.
Wegner, The Disclosure Requirements of the 1952 Patent Act: Looking
Back and a New Statute for the Next Fifty Years, 37 AKRON L. REV. 243,
243 (2004) (“The great bulk [of the 1952 Act] was a mere codification of
principles, going back in some cases to the earliest patent laws of the
eighteenth century ....”).
57

See supra section II.B,

58

See, e.g., In re Ngai, 367 F.3d 1336 (Fed. Cir. 2004).

59

130 S.Ct. 3218 (June 28, 2010).

22
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does not arise solely in connection with claims to § 101 “process[es].”60
Moreover, none of the Court’s reasoning in Bilski affects the operation of
the printed matter doctrine.
As discussed in Section II.B, the printed matter doctrine’s functional
role in preempting inapposite analyses of differences between the claimed
invention and the prior art is essentially complementary to that of the
judicially created exceptions to patentable subject matter affirmed in Bilski
and Diehr. Thus, even though the Supreme Court in these decisions has
required an “invention as a whole” approach to § 101 patent-eligible subject
matter analysis,61 this requirement has not affected the printed matter
doctrine’s reliance on “patentable weight” considerations, as the post-Diehr
decisions of the Federal Circuit show.62

Since Bilski, the court has

continued to treat the printed matter doctrine as operative and relevant to
patentability analysis.63

60

See CHISUM, supra (“‘[P]rinted matter’ by itself did not constitute a

‘manufacture’”).
61

See Bilski, 130 S.Ct. at 3230 (citing Diehr, 450 U.S. at 188),

62

See, e.g., In re Ngai, 367 F.3d 1336 (Fed. Cir. 2004).

63

See King Pharmaceuticals, Inc. v. Eon Labs, Inc., 616 F.3d 1267,

1278-79 (Fed. Cir. Aug. 2, 2010) (citing printed matter cases as persuasive
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The Bilski Court clarified that the only exceptions to patentable subject
matter supported by the Court’s precedents are for laws of nature, physical
phenomena, and abstract ideas,64 definitively retiring the idea of a
categorical exclusion for business methods.65 The printed matter doctrine’s
precedential support, however, is in no way undermined by the Court’s
repudiation of the supposed “business method” exception. While it may be
observed that the printed matter doctrine originated in part from cases
involving printed business forms,66 the applicability of the doctrine has
never been limited to business methods.67

Moreover, since the early

business-form cases, the role of the printed matter doctrine has developed
independently of any putative justification for excluding the category of
business methods from patentability.68

authority for point-of-novelty analysis of method claim).
64

130 S.Ct. at 3226.

65

Id. at 3228.

66

See, e.g., Hotel Security Checking Co. v. Lorraine, 160 F. 467 (2d

Cir. 1908); United States Credit System Co. v. American Credit Indemnity
Co., 59 F. 139 (2d Cir. 1893).
67

See, e.g., In re Ngai, 367 F.3d 1336 (Fed. Cir. 2004).

68

See, e.g., In re Nuijten, 500 F.3d 1346, 1365 (Fed. Cir. 2007) (Linn,

24
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In summary, the printed matter doctrine continues to serve alongside

other judicial exclusions, fulfilling an important role in maintaining the
integrity of patentability doctrine where novelty and nonobviousness
inquiries would improperly be directed at the content, form and
management of stored information rather than the functionality conferred by
the information upon the underlying substrate.

III. OLIGONUCLEOTIDES UNDER THE PRINTED MATTER DOCTRINE

A. Locus of the Inventive Contribution

J., concurring-in-part and dissenting-in-part) (describing the printed matter
doctrine as “potentially more apposite as a consequence of the ‘useful’
requirement of § 101”); Boggs v. Robertson, 13 U.S.P.Q. 214, 214 (D.C.
Sup. Ct. 1931) (applying the doctrine as an extension of the abstract ideas
exception); see also supra Section II.B (describing the doctrine’s
complementary role to the exceptions for laws of nature, physical
phenomena, and abstract ideas); Collins, supra note 22, at 1402 (arguing
that the abstract ideas exception “comes the closest to a source of support
for the doctrine”).
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The synthesis and use of isolated DNA oligonucleotides as
hybridization probes has been known in the published literature since at
least 1975.69

Oligonucleotides as gene probes differ from the

oligonucleotides used in prior art hybridization probe procedures only with
respect to the nucleotide sequences carried thereon.70 Thus, the inventive
contributions of the claimed oligonucleotide compositions subsist merely in
the nucleotide sequence information stored in the claimed molecules.71
By structure and function, DNA oligonucleotides are disposed to store
nucleotide sequence information in a manner analogous in all relevant
respects to other substrates that may be more intuitively recognizable as

69

See Edwin Mellor Southern, Detection of Specific Sequences Among

DNA Fragments Separated by Gel Electrophoresis, 98 J. MOLECULAR
BIOLOGY 503 (1975).
70

See, e.g., U.S. Patent No. 5,198,338, col. 3 (issued May 30, 1993)

(describing the use of Southern hybridization with isolated DNA
olignoucleotide probes “of a suitable hybridizable length (generally longer
than 15 nucleotides)” for the detection of T-cell malignancy).
71

See Collins, supra note 22, at 1390 (“The difference between a newly

isolated and purified strand of DNA and prior art DNA molecules resides in
the content of the DNA-as-information. . .”).
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information storage media.72 Structurally, characters comprising textual
information are physically represented on a laser-printed page by defined
patterns of toner powder fused to a paper surface.73 Similarly, nucleotide
sequence information is physically represented in the DNA molecule by
four defined types of submolecular units called “bases,” wherein each base
is bonded to a 5-carbon sugar that has a phosphate group attached to form a

72

Admittedly, all chemical structures carry structural information. See

Dan L. Burk, The Problem of Process in Biotechnology, 43 HOUS. L. REV.
561, 583-84 (2006) (“Due to its size, DNA can carry a very large amount of
structural information, but this structural encoding is similarly the case for
all biological macromolecules and indeed is at some greater or lesser degree
true of all chemical structures.”); Collins, supra note 22, at 1389 n.44
(noting that it would be “a conceptual error to frame DNA as unique in
raising the question of whether molecules are information with content”).
Significantly, however, gene probes are the subjects of such routine
methods of synthesis and use that any inventive contributions necessarily
reside in the sequence information itself.
73

See

Laser

Printer,

WIKIPEDIA

Laser_printer> (accessed Nov. 28, 2010).

<http://en.wikipedia.org/wiki/
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sequential unit called a “nucleotide.”74 The resulting structure in each case
physically manifests the specific information stored in the substrate, thereby
enabling that information to be retrieved.
Functionally, laser printing stores textual information on a paper
substrate through a computer-automated procedure that sequences and
controls the process of placing and fusing the toner powder onto the page.75
Analogously, automated oligonucleotide synthesis stores nucleotide
sequence information in a DNA molecule through a computer-automated
procedure that sequences and controls the process of placing and binding
nucleotides onto the molecule, which is covalently bonded to a solid
support.76 The user of an oligonucleotide synthesizer merely has to type in

74

See In re O’Farrell, 853 F.2d 894, 896 (Fed. Cir. 1988).

75

See Laser Printer, supra.

76

Oligonucleotide synthesis dates back to the early 1950s, soon after

the discovery of the structure of DNA. See Daniel M. Brown, A Brief
History

of

Oligonucleotide

Synthesis,

in

20

PROTOCOLS

FOR

OLIGONUCLEOTIDES AND ANALOGS 1, 1 (1993). Phosphotriester technology
for oligonucleotide synthesis was primarily developed in the 1960s and
1970s and refined and popularized in the 1980s. See Brown, supra, at 7-9;
see also Keiichi Itakura et al., Synthesis and Use of Synthetic
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the sequence and “press[] a few buttons.”77

Nucleotide sequence

information can subsequently be retrieved from a DNA oligonucleotide
using modern sequencing procedures.78
While the fixation of nucleotide sequence information in the DNA

Oligonucleotides, 53 ANN. REV. BIOCHEMISTRY 323, 353 (1984) (“[T]he
chemical synthesis of oligodeoxyribonucleotides has become a routine
laboratory procedure.”). In phosphotriester synthesis, the most widely used
methodology, there are four steps in each nucleotide addition, and at each
step appropriate compounds are added and washed out as the reaction
proceeds. The four steps are: (1) de-blocking of the DMT group on the last
nucleotide added, (2) coupling to the next nucleotide, (3) capping against
any unreacted nucleotides, and (4) oxidation of the linkage to render it
stable.

See

Oligonucleotide

Synthesis,

WIKIPEDIA

<http://en.wikipedia.org/wiki/Oligonucleotide_synthesis#Synthetic_cycle>
(visited Nov. 28, 2010).
77

See Richard Pon, Solid-Phase Supports for Oligonucleotide Synthesis,

in 20 PROTOCOLS FOR OLIGONUCLEOTIDES AND ANALOGS 465, 465 (1993).
78

See Enzo Biochem, Inc. v. Gen-Probe, Inc., 323 F.3d 956 (Fed. Cir.

2002) (finding that one of ordinary skill can use known sequencing
techniques to obtain nucleotide sequences from deposited DNA molecules).
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molecule occurs on an intramolecular level, the microscopic scale of this
phenomenon does not belie the fact that DNA oligonucleotides are
analogous in structure and function to other physical substrates that store
and manifest information as printed matter, such as laser-printed paper.
Any

structural

differences

between

the

claimed

oligonucleotide

compositions and prior art DNA oligonucleotides are simply the physical
manifestation of differences in nucleotide sequence information as it is
stored in the respective molecular substrates. Under the printed matter
doctrine,

therefore,

any

inventive

contributions

of

the

claimed

oligonucleotide contributions should be found to subsist merely in stored
information.

B. Inapposite Patentability Inquiries

As explained in section II.B supra, the printed matter doctrine serves to
pre-empt the diversion of patent law’s novelty and nonobviousness analyses
into information-management considerations unrelated to progress in the
field of the underlying invention.

The analysis of the patentability of

oligonucleotide probes is uniquely susceptible to such diversion, because of
two interrelated facts. First, as the Federal Circuit has recently explicitly
recognized, general methods of making isolated DNA oligonucleotides of
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arbitrary sequence have long been well known.79 Second, large databases
providing

nucleotide

sequence

information,

but

not

listing

all

oligonucleotide subsequences thereof, have been available to the public
since the early 1980s.80
At least until recently, the Federal Circuit has characterized both of
these facts as largely irrelevant to the novelty and nonobviousness analyses
of claims to particular isolated DNA oligonucleotides. In In re Deuel,81 the
court held that the availability of general methods of making isolated DNA
molecules “is essentially irrelevant to the question whether the specific
[claimed] molecules themselves would have been obvious” to one of

79

See In re Gleave, 560 F.3d 1331, 1336 (Fed. Cir. 2009) (finding prior

art to be enabling based on applicant’s admission that “it is well within the
skill of an ordinary person in the art to make any oligodeoxynucleotide
sequence”); Brown, supra note 76.
80

See

GenBank,

WIKIPEDIA<

http://en.wikipedia.org/

wiki/GenBank#History> (visited Nov. 28, 2010); David S. Roos,
Bioinformatics: Trying to Swim in a Sea of Data, 291 SCIENCE 1260 (2001)
(noting GenBank “continues to more than double in size every year”).
81

51 F.3d 1552 (Fed. Cir. 1995).
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ordinary skill.82 Databases of nucleotide sequences, without more, typically
do not anticipate claims to isolated oligonucleotides comprising specific
subsequences thereof, because such databases usually do not teach all
limitations of an isolated oligonucleotide claim, e.g., by listing the sequence
of every such oligonucleotide.83
Gleave implies that the patentability analysis of claimed DNA
oligonucleotides would be very different if scientists were in the practice of
publishing lists of oligonucleotide subsequences in addition to the fulllength sequences from which they were derived. In Gleave, the Federal
Circuit reviewed the Patent Office’s rejection of a claim to an antisense
DNA oligonucleotide substantially complementary to genes encoding two
types of insulin-dependent growth factor binding protein.84 The examiner
imposed, and the Board approved, a § 102(b) rejection over a reference that

82

Id. at 1559; but see In re Kubin, 561 F.3d 1351, 1358-59 (Fed. Cir.

2009) (noting the Supreme Court’s repudiation of Deuel to the extent that
Deuel foreclosed arguments that a combination of elements was “obvious to
try”).
83

See generally In re Gleave, 560 F.3d at 1336-38 (discussing different

treatment of lists and genera under anticipation case law).
84

Id.
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listed each of the more than 1400 fifteen-base-long sense oligonucleotides
contained in one of the genes and suggested making antisense
oligonucleotides

capable

oligonucleotides.85

of

interacting

with

the

listed

sense

Noting that “a person of ordinary skill in the art

equipped with an IGFBP sequence is admittedly capable of envisioning
how to make any antisense sequence,” the court found the reference to
anticipate all of the listed sense oligonucleotides and their antisense
counterparts.86
That the proliferation of nucleotide sequences in public databases has
not

been

accompanied

by

equally

extensive

and

particularized

documentation of oligonucleotide sequences does not reflect limitations in
the state of the art in biotechnology, but norms in scholarly communication.
Given any long nucleotide sequence, it is a trivial matter to identify all of
the oligonucleotides of a given length contained therein; to list all of them
would contribute nothing to the advancement of science and be a frivolous
waste of space. It is not surprising that the lengthy oligonucleotide listing
cited as prior art in Gleave was from a patent application rather than a

85

Id. at 1333-34.

86

Id. at 1338.
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professional scientific publication.87
It is an equally trivial (though scientifically uninteresting) matter to list
all oligonucleotide sequences of a given length that can be made with
known synthesis techniques, and thereby to generate a defensive publication
that anticipates a broad class of oligonucleotide compositions.

As I

demonstrated in a previous article,88 the potential impact of such defensive
publications on the patentability of oligonucleotides is limited only by the
capacity of digital storage media.89
In March 2002, I prepared a text document entitled “On the Preparation
and Utilization of Isolated and Purified Oligonucleotides,” containing (1) a
technical explanation of how to make and use isolated and purified
oligonucleotides of arbitrary sequence (derived from the presumably
enabling specifications of previously issued patents), and (2) a computergenerated list of 11 million nucleotide sequences 8 to 12 bases in length that
could be made and used by the disclosed methods.90 This document was
recorded on CD-ROM and deposited in the University of North Carolina

87

Id. at 1333.

88

See Chin, supra note 11.

89

See id. at 1021-23.

90

See id. at 1036-38 & n. 410.
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School of Law’s library, where it was indexed, cataloged and shelved under
the Library of Congress subject heading for oligonucleotides on March 14,
2002.91 This “shotgun reference” has been effective § 102(b) prior art
against oligonucleotide composition claims filed on or after March 15,
2003.92

91

See id. at 1010.

92

See 35 U.S.C. § 102(b).

As of October 15, 2010, the CD-ROM has been cited in the prosecution
history of 39 issued patents, including 35 whose applications originally
contained oligonucleotide composition claims. See U.S. Patents Nos.
6946267, 6953669, 7049067, 7087733, 7090980, 7098192, 7105319,
7108973, 7132233, 7166430, 7176181, 7186537, 7198898, 7229976,
7291725, 7339041, 7342109, 7345161, 7393641, 7393950, 7407943,
7414033, 7416725, 7468431, 7495094, 7514241, 7553618, 7589190,
7618947, 7622455, 7678895, 7700574, 7709628, 7718628, 7732590,
7737264, 7759318, 7759479.

In all 35 cases, the oligonucleotide

composition claims were either canceled or narrowed by amendment to
exclude sequences of 8 to 12 bases in length. In one case, the patent
examiner also cited the reference in a § 103 rejection of several method
claims. See U.S. Patent No. 7090980 (final rejection of Oct. 14, 2005).
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Fig. 1.

35

Impact of the CD-ROM reference on patentability of

oligonucleotides.93

The “shotgun reference” was limited to 11 million sequences only by
the capacity of a CD-ROM in 2002. As Fig. 1 illustrates, at any given time,
the feasibility of producing a shotgun reference as effective prior art against
oligonucleotides of a given length is dependent on the availability of highcapacity, low-cost digital media. In Fig. 1, the impact of the CD-ROM

93

Chin, supra note 11, at 1022.
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reference is represented by the white segment that has been carved out of
the shaded rectangle; the right scale indicates that as of 2003, broad claims
to oligonucleotides of 8 to 12 bases were no longer patentable. As the data
points plotted against the left scale illustrate, continuing advances in
information storage technology may be expected to make it feasible to
generate and publish shotgun references covering oligonucleotides of everincreasing lengths.
There is a deep incongruity in these results.

Known methods of

synthesizing arbitrary isolated DNA oligonucleotides represent a significant
part of the state of the art in biotechnology.94 In contrast, the existence (or
nonexistence) of shotgun references listing the sequences of arbitrary
isolated oligonucleotides is of no significance to the state of the art in
biotechnology.

The feasibility of generating and publishing a shotgun

reference of a given scope is determined solely by the state of information
storage technology. Yet patent doctrine holds that such a sequence listing
anticipates an oligonucleotide composition claim,95 while oligonucleotide
synthesizers do not even render such a claim obvious.96

94

See Brown, supra note 76.

95

See Gleave, 560 F.3d at 1336-38.

96

See Deuel, 51 F.3d at 1559.
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The CD-ROM reference (and the patent system’s response thereto)
concretely demonstrates that the novelty and nonobviousness analyses of
oligonucleotide composition claims are deeply and inextricably contingent
on information-management considerations that are irrelevant to the state of
the art in biotechnology.

The printed matter doctrine can serve its

functional role by obviating such analyses.97

C. The Information-Substrate Relationship

“Additional advantageous activity” may distinguish a claimed species as
nonobvious over a known genus.98

While the specific utility of

oligonucleotides in testing for longer, clinically significant genetic
sequences may represent “additional advantageous activity” in which
nonobviousness subsists, this utility is not the result of a “new and
unobvious functional relationship between the printed matter and the
substrate.”99 Accordingly, the printed matter doctrine should be applied to
invalidate gene probe claims.

97

See section II.B.

98

See In re Albrecht, 514 F.2d 1389 (C.C.P.A. 1975).

99

In re Gulack, 703 F.2d at 1386.
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In Gulack, the claimed invention was an endless band on which had

been printed the first P–1 significant digits in the repeating decimal
expansion of 1/P, where P is a prime number.100 This number has the
property that cyclic shifts of the digits produce integer multiples of the
original number.101 The inventor claimed the band as “an educational and
recreational mathematical device” that would display cyclic shifts of the
original number, whose multiplicative properties might be used, inter alia,
“to perform magic tricks or to display various aspects of number theory.”102
The specification and claims included such embodiments as a belt, hatband,
necklace, or ring.103
The examiner rejected several claims under the printed matter doctrine,
and the Board affirmed, finding “no functional relationship of the printed
material to the substrate.”104 The court reversed, finding that “the digits of

100

101

See id. at 1383.
See id.

For example, the decimal expansion of 1/7 is

.142857142857…. A cyclic shift of the number 142857 has the property
that 428571=3*142857.
102

See id.

103

See id.

104

See id. at 1384.

GENE PROBES AS UNPATENTABLE PRINTED MATTER
Gulack’s invention are functionally related to the band.”105
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The court

reasoned:
The appealed claims, on the other hand, require a particular
sequence of digits to be displayed on the outside surface of a
band. These digits are related to the band in two ways: (1)
the band supports the digits; and (2) there is an endless
sequence of digits — each digit residing in a unique position
with respect to every other digit in an endless loop. Thus, the
digits exploit the endless nature of the band.106
Crucial to the court’s analysis was its finding that “there is an endless
sequence of digits” that could not have been stored on anything other than a
distinctive kind of substrate; i.e., one with an “endless nature.” Gulack’s
specification, however, teaches that “the sequence of digits imprinted on the
band” is the finite sequence of P–1 digits described above.107 The Gulack
court thus appears to have construed “the digits of Gulack’s invention” as
intrinsically incorporating a special mathematical property that could be
manifested only by also including all cyclic shifts of those digits.

105

Id. at 1385.

106

Id. at 1386-87.

107

See id. at 1383.
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In contrast, the nucleotide sequences of the claimed oligonucleotide

compositions do not possess any intrinsic property that necessitates a
distinctive kind of substrate.

An oligonucleotide synthesizer fixes the

sequence information of the claimed oligonucleotides into the substructures
of a DNA molecule in the same way as it processes any other sequence
information.108
It may be argued that oligonucleotides manifest higher-order structures
that dispose them to hybridize specifically with clinically significant
complementary DNA sequences. From a functional standpoint, however,
the causal disposition of oligonucleotides to hybridize with complementary
DNA sequences — the only causal disposition that the oligonucleotides of a
typical gene probe claim have in common109 — is common to all

108

See supra note 76.

109

The universe of oligonucleotides is structurally diverse, see, e.g.,

M.A. Viswamitra, Structural Diversity in DNA: From Monomer Structures
to Oligonucleotides, 47 COLD SPRING HARBOR SYMP. QUANTITATIVE
BIOLOGY 25 (1983). Typical gene probe claims are broad enough to cover a
diverse group of oligonucleotides, i.e., by using the open transitional term
“comprising” and covering all sufficiently long subsequences of a recited
longer sequence. See Chambers, supra note 15. Because of this diversity,
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oligonucleotides, and is neither new nor unobvious.110
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The sequence

information of a group of claimed oligonucleotides possesses no intrinsic
property that distinguishes the functional properties of their underlying
substrates from those of other oligonucleotides.

such claims can ensure a common causal property only by picking out
precisely those oligonucleotides that hybridize with a specified DNA
sequence.
In contrast to oligonucleotides, longer DNA molecules that encode
proteins with metabolic functions may have both meaning that is semantic
and information content that is non-semantic, see Peter Godfrey-Smith,
Genes Do Not Code for Phenotypic Traits, in CONTEMPORARY DEBATES IN
PHILOSOPHY OF SCIENCE 275, 281-94 (Christopher Hitchcock ed. 2004), and
therefore might not be covered by the printed matter doctrine. Cf. In re
Fisher, 421 F.3d 1365, 1373 (Fed. Cir. 2005) (finding expressed sequence
tags that were “unable to provide any information about the overall
structure let alone the function of the underlying [protein-encoding] gene”
to lack patentable utility as research tools).
110

See In re Deuel, 51 F.3d at 1554-55 (explaining that DNA probes

“exploit the fact that the bases in DNA always hybridize in complementary
pairs”).
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To the extent that a hybridization reaction involving a claimed

oligonucleotide is recognized as having specific utility, it is by virtue of the
semantic properties that scientists have attached to the complementary DNA
sequence, not a new and unobvious functional relationship between the
sequence information and the molecular substrate.111 While hybridization
reactions involving the claimed oligonucleotide probes may impart new and
unobvious information regarding cancer, such information is “useful and
intelligible only to the human mind” and cannot confer patentability.112

111

See U.S. Patent No. 5,747,282, col. 7 (describing the observation of

“large extended families . . . with multiple cases of breast cancer” to support
scientists’ inferences regarding the locus of the BRCA1 gene); see also
Godfrey-Smith, supra note 109, at 283 (arguing that apart from protein
synthesis, causal claims linking genes and phenotypic traits are grounded in
semantic description).
112

See In re Lowry, 32 F.3d 1579 (Fed. Cir. 1994) (citing In re

Bernhart, 417 F.2d 1395, 1399 (C.C.P.A. 1969)) (“The printed matter cases
‘dealt with claims defining as the invention certain novel arrangements of
printed lines or characters, useful and intelligible only to the human
mind.’”); see also Collins, supra note 22, at 1383 (“Standing alone, newly
invented semiotic meanings are not eligible for patent protection. Similarly,
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CONCLUSION

This is admittedly an unusual argument. The courts have not previously
applied the printed matter doctrine to preclude the patenting of DNA
molecules.113 It has only been relatively recently, however, that unrelated
but contemporaneous developments in biotechnology and information
technology have thrown the doctrinal incongruity described above into high
relief. It is only a matter of time until information technology supports the
publication of shotgun references that foreclose the patenting of
oligonucleotides of any given length. The courts can declare an end to this
irrelevant waiting game by holding that the printed matter doctrine
precludes the patenting of oligonucleotides capable of being synthesized by
known general methods.

attaching new semiotic meanings to old worldly things does not make the
worldly things patentable.”).
113

See Collins, supra note 22, at 1389 n. 40 (noting that “printed matter

challenges have not been brought against gene patents”).

